Literature DB >> 32527607

LRP10 variants in progressive supranuclear palsy.

Leonie J M Vergouw1, Shamiram Melhem1, Laura Donker Kaat2, Wang Z Chiu1, Demy J S Kuipers3, Guido Breedveld3, Agnita J W Boon4, Li-San Wang5, Adam C Naj6, Elizabeth Mlynarksi7, Laura Cantwell7, Marialuisa Quadri3, Owen A Ross8, Dennis W Dickson8, Gerard D Schellenberg9, John C van Swieten1, Vincenzo Bonifati3, Frank Jan de Jong10.   

Abstract

The aim of this study was to explore whether variants in LRP10, recently associated with Parkinson's disease and dementia with Lewy bodies, are observed in 2 large cohorts (discovery and validation cohort) of patients with progressive supranuclear palsy (PSP). A total of 950 patients with PSP were enrolled: 246 patients with PSP (n = 85 possible (35%), n = 128 probable (52%), n = 33 definite (13%)) in the discovery cohort and 704 patients with definite PSP in the validation cohort. Sanger sequencing of all LRP10 exons and exon-intron boundaries was performed in the discovery cohort, and whole-exome sequencing was performed in the validation cohort. Two patients from the discovery cohort and 8 patients from the validation cohort carried a rare, heterozygous, and possibly pathogenic LRP10 variant (p.Gly326Asp, p.Asp389Asn, and p.Arg158His, p.Cys220Tyr, p.Thr278Ala, p.Gly306Asp, p.Glu486Asp, p.Arg554∗, p.Arg661Cys). In conclusion, possibly pathogenic LRP10 variants occur in a small fraction of patients with PSP and may be overrepresented in these patients compared with controls. This suggests that possibly pathogenic LRP10 variants may play a role in the development of PSP.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Genetics; LRP10; Progressive supranuclear palsy; Rare variants

Mesh:

Substances:

Year:  2020        PMID: 32527607      PMCID: PMC8281359          DOI: 10.1016/j.neurobiolaging.2020.04.016

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  31 in total

1.  Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).

Authors:  I Litvan; Y Agid; J Jankovic; C Goetz; J P Brandel; E C Lai; G Wenning; L D'Olhaberriague; M Verny; K R Chaudhuri; A McKee; K Jellinger; J J Bartko; C A Mangone; R K Pearce
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

2.  LRP10 in α-synucleinopathies.

Authors:  Lasse Pihlstrøm; Lucia Schottlaender; Viorica Chelban; Henry Houlden
Journal:  Lancet Neurol       Date:  2018-11-13       Impact factor: 44.182

Review 3.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

4.  Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Authors:  Günter U Höglinger; Nadine M Melhem; Dennis W Dickson; Patrick M A Sleiman; Li-San Wang; Lambertus Klei; Rosa Rademakers; Rohan de Silva; Irene Litvan; David E Riley; John C van Swieten; Peter Heutink; Zbigniew K Wszolek; Ryan J Uitti; Jana Vandrovcova; Howard I Hurtig; Rachel G Gross; Walter Maetzler; Stefano Goldwurm; Eduardo Tolosa; Barbara Borroni; Pau Pastor; Laura B Cantwell; Mi Ryung Han; Allissa Dillman; Marcel P van der Brug; J Raphael Gibbs; Mark R Cookson; Dena G Hernandez; Andrew B Singleton; Matthew J Farrer; Chang-En Yu; Lawrence I Golbe; Tamas Revesz; John Hardy; Andrew J Lees; Bernie Devlin; Hakon Hakonarson; Ulrich Müller; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-06-19       Impact factor: 38.330

Review 5.  Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

Authors:  J J Hauw; S E Daniel; D Dickson; D S Horoupian; K Jellinger; P L Lantos; A McKee; M Tabaton; I Litvan
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

6.  Inferior olivary hypertrophy is uncommon in progressive supranuclear palsy.

Authors:  Omi Katsuse; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2004-05-15       Impact factor: 17.088

7.  Frontal presentation in progressive supranuclear palsy.

Authors:  L Donker Kaat; A J W Boon; W Kamphorst; R Ravid; H J Duivenvoorden; J C van Swieten
Journal:  Neurology       Date:  2007-08-21       Impact factor: 9.910

Review 8.  Familial progressive supranuclear palsy: a literature review.

Authors:  Shinsuke Fujioka; Jay A Van Gerpen; Ryan J Uitti; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Neurodegener Dis       Date:  2013-09-24       Impact factor: 2.977

9.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

10.  Progressive Ataxia and Palatal Tremor: Think about POLG Mutations.

Authors:  Marie Mongin; Cécile Delorme; Timothée Lenglet; Claude Jardel; Catherine Vignal; Emmanuel Roze
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-05-02
View more
  1 in total

1.  Clinical and Pathological Phenotypes of LRP10 Variant Carriers with Dementia.

Authors:  Leonie J M Vergouw; Hanneke Geut; Guido Breedveld; Demy J S Kuipers; Marialuisa Quadri; Annemieke J M Rozemuller; John C van Swieten; Frank Jan de Jong; Wilma D J van de Berg; Vincenzo Bonifati
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.